NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Pharmaceutical Retailers · USD

Pomdoctor Limited (POM) Stock Analysis

Pomdoctor Limited (POM) is a Pharmaceutical Retailers stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

POM

$3.01

+$2.35 (+352.77%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare POM with… →

POM Key Statistics

As of Oct 21, 2026
Trading
Open
$0.95
Previous Close
$0.66
Day's Range
0.69–3.01
52-Week Range
0.43–115.74
Volume
33.60M
Valuation
Market Cap
$27.90M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.07
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.84
Financials (FY)
Revenue (FY)
$399.91M+16.74%
Net Income (FY)
−$212.58M
Profit marginThe share of revenue left as profit after all costs and taxes.
−90.16%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.59M
1-Year Return
−96.11%
Dividend and dates
Avg Volume
64.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, POM closed at $3.01, −96.11% over 1 year.

Pomdoctor Limited (POM) has a market capitalization of $27.90M.

In fiscal 2025, POM reported revenue of $399.91M.

POM Stock Return by Calendar Year

Pomdoctor Limited (POM) return since Oct 2025: what $10,000 became

1 year
$10,000 $389
−96.11%
Since Oct 2025
$10,000 $415
−95.85%

If you had invested $10,000 in Pomdoctor Limited (POM) at the close on October 8, 2025, the earliest close on record here, it would have been worth $415 at the close on October 21, 2026: −95.85% in total, −95.38% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−43.31%
2025 (partial year)−92.68%

As of October 21, 2026.

POM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$399.91M−$212.58M−53.2%
2024$342.56M−$143.36M−41.9%
2023$304.85M−$145.39M−47.7%
2022$245.22M−$125.51M−51.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$399.91M$52.28M−$116.37M−$212.58M−53.2%
2024$342.56M$47.69M−$23.36M−$143.36M−41.9%
2023$304.85M$38.72M−$20.32M−$145.39M−47.7%
2022$245.22M$54.86M−$3.31M−$125.51M−51.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

POM Valuation vs Pharmaceutical Retailers Median

Median of 6 stocks
MetricPOMPharmaceutical Retailers medianvs median
P/S ratio0.070.240.3x the median
Profit margin−90.16%−17.34%72.8 pts below

Medians across 6 Pharmaceutical Retailers stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Pomdoctor Limited (POM) at $27.90M. It is classified in the Pharmaceutical Retailers industry, within the Healthcare sector. Headcount on file is 165.

The most recent close on file for POM is $3.01, dated October 21, 2026. That is +$2.35 (+352.77%) against the previous close. The 52-week range on file runs from $0.43 to $115.74. The latest close sits 595.15% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $399.91M. That is +16.74% against the prior fiscal year, when revenue was $342.56M. The same year closed with a net loss of $212.58M. Profit margin runs at −90.16%. That is 72.8 percentage points below the Pharmaceutical Retailers median of −17.34%. Earnings per share on a trailing basis come to −6.84.

Across the 4 fiscal years on file, revenue moves from $245.22M in 2022 to $399.91M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 0.07 times revenue. On price-to-sales that is 0.3 times the Pharmaceutical Retailers median of 0.24. 6 Pharmaceutical Retailers companies report these metrics, and the medians quoted come from that group.

Annualized volatility over the trailing 1 year is 419.29%. The trailing one-year total return is −96.11%.

Growth & Income

No dividend is on file for POM.

So far in 2026 the total return is −43.31%.

Peer Comparison

Pomdoctor Limited (POM) operates in the Pharmaceutical Retailers industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pomdoctor Limited POM $27.90M —
High Tide Inc. HITI $240.69M —
TelyRx Holdings Inc. TELY.TO CA$66.48M —
PetMed Express, Inc. PETS $25.80M —

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Pharmaceutical Retailers Stocks

HITI

High Tide Inc.

$240.69M

 TELY.TO

TelyRx Holdings Inc.

CA$66.48M

 PETS

PetMed Express, Inc.

$25.80M

 SCNX

Scienture Holdings, Inc.

$4.77M

 RDGT

Ridgetech, Inc.

$2.98M
View all Pharmaceutical Retailers stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Pomdoctor Limited

Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company in involved in internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company was founded in 2010 and is headquartered in Guangzhou, China.

Visit website →